The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.
Age: Women aged 19-85 years.
Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer.
Refractory: Disease progression during platinum-based chemotherapy.
Resistant: Progression within 6 months (24 weeks) post-platinum therapy.
≥2 distant metastases (excluding retroperitoneal lymph nodes, pleural effusion, and localized skin metastases).
Contraindications to paclitaxel per approved domestic labeling.
Hypersensitivity history to paclitaxel or PIPAC devices.
NYHA Class ≥II heart failure